Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Innovation Pharmaceuticals IPIX
(Total Views: 302)
Posted On: 09/08/2018 2:30:36 PM
Post# of 72447
Avatar
Posted By: tryz
Celgene Corporation (CELG) CEO Mark Alles on Citi's 13th Annual Biotech Conference (Transcript)

Sep. 6, 2018 7:05 PM•CELG

Celgene Corporation (NASDAQ:CELG)

Citi's 13th Annual Biotech Conference Call

September 6, 2018 12:00 PM ET


Mark Alles

That that’s the most important part for our industry. Do you recover the legitimate R&D costs that for us now include, for example, the spectacular disappointment of GED-0301, where we bought it for $700 million upfront. We developed it until the point, where it failed in Phase III for Crohn’s. That’s at least $1.2 billion out the door at risk......



This was just recent due diligence I found and find it very ironic and intriguing that IPIX was invited to speak about Brilacidin ongoing medicinal capabilities in its treatment of Chron's and inflammatory bowel syndrome with Celgene being the sponsorship to the symposium in New York Medical Academy in this coming November.....coincidence or novel approach to maybe fascinating idea! ......my thoughts, tryz













(3)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site